Views & Analysis Almirall gets in on the eczema action Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
